共 50 条
- [1] MV140 sublingual vaccine proves promising in fighting recurrent urinary tract infections in women CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2023, 18 (02): : 31 - 31
- [2] MV140 sublingual vaccine proves promising in fighting recurrent urinary tract infections in women CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2024, 18 (02):
- [3] An Effective Sublingual Vaccine, MV140, Safely Reduces Risk of Recurrent Urinary Tract Infection in Women PATHOGENS, 2023, 12 (03):
- [5] Effectiveness and health cost analysis between immunoprophylaxis with MV140 autovaccine, MV140 vaccine and continuous treatment with antibiotics to prevent recurrent urinary tract infections ACTAS UROLOGICAS ESPANOLAS, 2023, 47 (01): : 27 - 33
- [6] IMPACT OF MV140 ON PATIENT RELATED BURDEN OF DISEASE ASSOCIATED WITH THE MANAGEMENT OF RECURRENT URINARY TRACT INFECTIONS (RUTI) JOURNAL OF UROLOGY, 2022, 207 (05): : E16 - E16
- [7] MV140 sublingual vaccine reduces recurrent urinary tract infection in women Results from the first North American clinical experience study CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2023, 18 (02): : 24 - 30
- [9] MV140 sublingual vaccine reduces recurrent urinary tract infection in women Results from the first North American clinical experience study CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2024, 18 (02): : 25 - 31